Navigation Links
Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives
Date:12/5/2007

Company Updates on Four Phase 2 Clinical Trials Dow AgroSciences CEO Discusses Future Opportunities with Sangamo Technology

NEW YORK, Dec. 5 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that the company will provide an update on milestones achieved in 2007 and preview objectives for 2008 during its annual Investor and Analyst Briefing held in New York City today.

Jerome Peribere, President and CEO of Dow AgroSciences will discuss the success of the two companies' collaboration to develop zinc finger DNA-binding protein (ZFP) technology for use in plant agriculture and Dow AgroSciences' future plans to commercialize the technology. Mr. Peribere will be joined by Edward Lanphier, Sangamo's President and CEO and other members of Sangamo's senior management team.

"We have been very pleased with the progress of our collaboration with Sangamo and by the success that we have had together to confirm our conviction that the ZFP platform has the ability to truly transform the field of plant genetics," commented Mr. Peribere. "We have established that Sangamo's ZFP technology can be used to regulate and modify genes in plants with great specificity and reliability. This enables significant savings in both the rate and cost of development of new crop products with improved traits, characteristics and regulatory designation. We envision that the application of ZFP-mediated gene modification and regulation will become a major component of our plant biotechnology process and, as we enter commercialization and sublicensing, will have a 'game-changing' role in the future of plant breeding."

"The past year has been an exciting and transformational period for Sangamo
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
3. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
4. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
5. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
6. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
7. Anaptys Biosciences Raises Over $33 Million in Series B Financing
8. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
9. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
10. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
11. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... TX (PRWEB) December 20, 2014 The ... a new injectable filler from respected cosmetic brand Juvéderm. ... occur naturally with age. The Medspa at Hendrick is ... development in skin care technology to its clients. , ... gel to be FDA-approved to treat the mid-face and ...
(Date:12/19/2014)... (HealthDay News) -- All children should have their eyesight ... every year, eye experts say. The new vision-screening ... of the U.S. National Center for Children,s Vision Health. ... group require screening for eye problems, particularly vision ... ("lazy eye") and strabismus (a disorder of eye alignment). ...
(Date:12/19/2014)... -- The cost of cancer treatment can cause financial ... Researchers examined data from 1,000 people in the ... lung cancer. Of those patients, almost 900 had finished ... had advanced cancer. Nearly half of the patients ... which was linked with a poorer health-related quality of ...
(Date:12/19/2014)... Dennis Thompson HealthDay ... -- Ebola,s entrance into the United States -- along ... mumps outbreak -- have highlighted cracks in the nation,s ... new health policy report released Thursday. Half of ... respond to infectious disease outbreaks. That was the main ...
(Date:12/19/2014)... NJ (PRWEB) December 19, 2014 ... Inside Patient Care: Pharmacy & Clinics™, an independent ... healthcare team treating and caring for patients inside ... primary care expands to provide optimal access to ... offers a forum for the team treating and ...
Breaking Medicine News(10 mins):Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2Health News:Preschoolers Need Eye Screening, Experts Say 2Health News:Cancer Treatment Costs Weigh Heavily on Patients, Study Finds 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 3Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 4Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 2Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 3
... on knowing when you,re ready to drive again , , WEDNESDAY, ... get behind the wheel again after orthopedic surgery or injury, but ... turning the key. , Orthopedic surgeons weigh in on the issue ... Joint Surgery . , "Deciding when a patient can return ...
... (OTC Pink Sheets: SNDY ) is pleased to announce that ... by over 10% compared to the same time period for 2007. ... $28,509 for the same month last year. This marks the second ... of October. , , The Mammo ...
... Dec. 10 GeneGo, Inc., a leading,provider of software ... ,today announced that A*STAR,s Singapore Immunology Network (SIgN) has ... will have access,to GeneGo,s MetaCore, training and advanced support. ... all SIgN researchers. , ...
... Three Skilled Nursing Facilities , , ... intense 18-month selection process, a proven commitment to clinical ... records (EMR) throughout Metropolitan Jewish Health System,s (Metropolitan) skilled ... Metropolitan, a nationally recognized nonprofit organization, operates Metropolitan ...
... Services, Goodwill, , , ... MDZ ), a leading provider of products and services ... 2008 performance. , Based on preliminary information, MDS expects ... $1,210 million to $1,220 million and adjusted EBITDA in the range ...
... While They,re Still Healthy Enough to Qualify , ... you,ve put off getting long term care insurance, should you ... health plan? "I wouldn,t advise it," says Denise Gott, Chairman ... of the nation,s most experienced long term care insurance agencies. ...
Cached Medicine News:Health News:Returning to the Road Tricky After Injury 2Health News:Solos Endoscopy, Inc. Increases Sales Revenue for October 2008 by Over 10% as Compared to Last Year 2Health News:A*STAR's Singapore Immunology Network Is the First GeneGo Center of Excellence in Asia 2Health News:Metropolitan Jewish Health System Awards Electronic Medical Records Contract to SigmaCare(R) 2Health News:Metropolitan Jewish Health System Awards Electronic Medical Records Contract to SigmaCare(R) 3Health News:MDS Provides Update on Fiscal 2008 Performance 2Health News:MDS Provides Update on Fiscal 2008 Performance 3Health News:MDS Provides Update on Fiscal 2008 Performance 4Health News:Obama Health Plan Not Likely to Embrace Long Term Care, Industry Leader Says 2
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/942kh3/micro_market ) ... Market Monitor: North American Dermatology Diagnostic Devices Market" ... http://photos.prnewswire.com/prnh/20130307/600769 Cosmetic surgeries ... resulted in fueling the overall demand of the ... these dermatology devices is to assist in identifying ...
(Date:12/19/2014)... , Dec. 18, 2014  Decision Resources Group ... the United States will increase to a ... be primarily driven by expansion in the large direct ... devices will be increasingly adopted due to the advantages ... Other key findings from Decision Resources Group,s coverage ...
(Date:12/19/2014)... , Dec. 18, 2014  RESMED INC. (NYSE: ... second quarter of fiscal year 2015 results on Thursday, January ... A press release with ResMed,s results will be issued after ... a webcast to discuss operating results and future outlook. ... p.m. US Pacific Time and the live webcast of the ...
Breaking Medicine Technology:Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3ResMed To Announce Second Quarter 2015 Results 2
... Index (BMI) Rebound Age, Can Predict Heart Disease and Calls for ... Children,s ... The results from the newest study,in a continuum of research on childhood ... reason for pediatricians to begin,measuring and monitoring body mass index (BMI) in ...
... Tissue Oncology, Society held in Seattle, Washington demonstrates clinical ... single agent in patients with ... chemo-insensitive sarcomas, NEW YORK, Nov. ... preliminary data demonstrating the,tolerability and clinical activity of KRX-0401 (perifosine) in ...
Cached Medicine Technology:New Risk Factor for Heart Disease Identified in Very Young Children, According to Study at American Heart Association Scientific Sessions 2New Risk Factor for Heart Disease Identified in Very Young Children, According to Study at American Heart Association Scientific Sessions 3Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 2Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 3Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 4Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 5Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 6
For the quantitative determination of Uric Acid in serum. Linearity: 25 mg/dl....
... for continuous, random access operation, the Elecsys ... to large volume laboratories that want to ... the simplicity, flexibility and Stat capabilities of ... be adapted to the changing needs of ...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...
... The SkanWasher 400 ... 96-well microplate washer with ... pumps. The individual pressure ... a very gentle wash ...
Medicine Products: